SAN DIEGO and SYDNEY, Australia, May 16, 2011 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold its 2011 Annual General Meeting of Stockholders on 23 May 2011, at 10:30 a.m. AEST (which is 5:30 p.m. on May 22, 2011 U.S. PDT) at the AGL Theatre in the Museum of Sydney, which is at the corner of Phillip and Bridge Streets.
If not attending in person, the meeting can be accessed in the United States by dialing 1-877-312-5413 five minutes prior to the scheduled start time. For callers in Australia, please dial 2 8223 9876. The meeting and the associated presentation materials may be accessed through the Investors section of the Company's website at under Events and Presentations. A replay of the meeting will be available on the Company's website after the meeting.
REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialisation of its proprietary, bioresorbable stent products. REVA's lead product, the ReZolve™ stent, combines REVA's proprietary stent design with a proprietary polymer that is metabolised and cleared from the body. The ReZolve stent is designed to offer full x-ray visibility, clinically relevant sizing and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of stent structure over time, the ReZolve stent may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA is in the process of finalising the design of its ReZolve stent and currently intends to initiate a pilot human clinical trial in the third quarter of 2011. REVA will require regulatory approval before it can begin selling the ReZolve stent.
This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to regulatory submissions and approvals; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials; our expectations with respect to the integrity or capabilities of our intellectual property position; our ability to commercialize our existing products; our ability to develop and commercialize new products; and our estimates regarding our capital requirements and financial performance, including profitability. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. REVA may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, described in "Risk Factors" in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on March 30, 2011. We may update our risk factors from time to time in our periodic reports or other current reports filed with the SEC.
CONTACT: Investor Enquiries: United States: Cheryl Liberatore REVA Medical, Inc. Director, Corporate Development +1 858 966-3045 Australia: David Allen or Alan Taylor Inteq Limited +61 2 9231 3322 Media Enquiries: Cannings Corporate Communications Michael Mullane + 61 414 590 296